ARTICLE | Company News
China Medical gets Asian rights to Vaximm's immunotherapy portfolio
September 28, 2018 7:55 PM UTC
China Medical System Holdings Ltd. (HKSE:867) gained an exclusive license from Vaximm AG (Basel, Switzerland) to develop and commercialize Vaximm's oral cancer immunotherapy pipeline in China, Hong Kong, Macau, Taiwan and other Asian countries. The deal excludes Japan, India and countries in western Asia. Vaximm also said China Medical will invest in its series B round.
China Medical also gained an option to license future Vaximm products...
BCIQ Target Profiles
Vascular endothelial growth factor (VEGF) receptor 2 (VEGFR-2) (KDR/Flk-1)